Osteoporosis Treatment Market
Number of pages: 100 | Report Format: PDF | Published date: 25 January, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market size value in 2021 |
US$ 12.5 billion |
|
Revenue forecast in 2030 |
US$ 17.18 billion |
|
Growth Rate |
CAGR of 3.6% from 2022 to 2030 |
|
Base year for estimation |
2021 |
|
Forecast period |
2022-2030 |
|
Historical Years |
2020 |
|
Segments covered |
Treatment Type, Administration Route, Distribution Channel, and Region. |
|
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
The global osteoporosis treatment market was valued at US$ 12.5 billion in 2021 and is expected to witness a CAGR of 3.6% during the forecast period from 2022 to 2030.
Market Fundamentals
Osteoporosis is a bone disease that occurs when the body suffers from high calcium deficiency for an extended period. Osteoporosis is a severe disorder wherein bones are weakened and become highly brittle; thus, can be easily broken (fractured) by a fall or, in extreme instances, sneezing or a little bump. Osteoporosis lacks a full-term cure, but effective treatment and therapy play a crucial role in maintaining and strengthening the bones. Osteoporosis therapy can reduce bone frangibility and stimulate bone growth by assisting the body in retaining a required amount of calcium. The treatment for osteoporosis involves medication, weight-bearing exercise, and a nutritious diet to help prevent bone loss or strengthen weak bones. Some complementary and alternative therapies are also used to control or heal osteoporosis without the need for the administration of drugs.
[4378034]
Market Dynamics
The main aim of osteoporosis treatment is to decrease or prevent mineral loss. It enhances bone density, avoids bone fractures, and reduces disease-related discomfort. The osteoporosis treatment market is a large industry and is expected to illustrate continuous growth during the forecasted timeframe. The development of the global osteoporosis market is primarily attributed to the rising incidence of osteoporosis among the population, primarily due to the increasing elderly population. According to WHO studies on osteoporosis, nearly 6.3% of men and 21.2% of women in the age group above 50 have osteoporosis. Almost 500 million people across the globe are likely to be affected by this disease. Additionally, the osteoporosis treatment market is also driven by an increased risk of bone fractures, and the launch of novel pharmacological therapy classes is driving the growth of the osteoporosis pharmaceuticals market. For instance, In Dec 2022, Asahi Kasei Pharma announced that their bag product of Reclast® for intravenous (i.v.) infusion 5 for the treatment of osteoporosis got listed on Japan's National Health Insurance (NHI) drug price standard. Moreover, growing public awareness about the latest & available therapies and drugs among the population is also expected to boost the market’s growth.
However, barriers like medicine patent expiration owing to increased risk factors hinder the overall market expansion. Furthermore, adverse effects of osteoporotic medications, such as hot flushes, vomiting, leg cramps, bowel changes, diarrhea, and others, are also limiting the market. Moreover, rigorous regulations, delays in FDA clearances, and product recalls/suspensions are also expected to hamper the market expansion by limiting product sales.
Market Ecosystem
The global osteoporosis treatment market has been analyzed from four perspectives: Treatment Type, Administration Route, Distribution Channel, and Region.
Osteoporosis Treatment Market by Treatment Type
[424231]
Based on treatment type, the global osteoporosis treatment market has been segmented into bisphosphonate, hormone replacement therapy, RANK ligand (RANKL) inhibitor, selective estrogen receptor modulator (SERMs), and others. The bisphosphonate segment holds the largest revenue share of the global osteoporosis treatment market owing to its comprehensive utilization as the first-line treatment for osteoporosis. The bisphosphonate segment is further sub-classified into alendronate, risedronate, ibandronate, zoledronic acid, and others. It is most effective in significantly lowering fracture risk (by 25% to 70% on average), depending on the fracture site. Bisphosphonate drugs are chemicals from inorganic pyrophosphate that have a high affinity for bone hydroxyapatite, block farnesyl pyrophosphate synthetase, and cause cell death, inhibiting bone resorption. Alendronate (ALN), risedronate (RIS), and zoledronic acid (ZOL) are most often used and recommended owing to their given documented effectiveness in increasing BMD (bone mass density) and lowering the risk of vertebral, non-vertebral, and hip fracture. However, its long-term usage has been linked to decreased bone turnover and increased bone brittleness. Furthermore, for individuals who have been using it for a long period (typically more than three years, with a median treatment length of 7 years), excessive prevention of bone resorption might raise the risk of mandibular osteonecrosis or atypical femoral fracture.
Osteoporosis Treatment Market by Administration Route
Based on the administration rote, the global osteoporosis treatment market has been bifurcated into oral and parental. The parental administrative route holds the largest revenue share in the global osteoporosis market. The growth of this market is majorly ascribed to its benefits compared to other routes. Parenteral administration allows for greater dosage and rate control, resulting in more predictable pharmacodynamic and pharmacokinetic characteristics. Furthermore, parental administration provides the advantage of the better capacity to promptly administer a precise amount of medication since it is injected straight into the tissue and circulatory system, skipping liver processing. In comparison, the oral segment is expected to illustrate steady growth during the projected timeline attributed to the product availability and preference of the physicians.
Osteoporosis Treatment Market by Distribution Channel
According to the distribution channel, the global osteoporosis treatment market is classified into online pharmacy, retail pharmacy, and hospital pharmacy. The hospital pharmacy segment registers the highest revenue share in the market. The growth of this segment can be attributed to a large patient pool resulting in higher patient visits. Additionally, the availability of advanced technologies and the presence of well-trained healthcare professionals further drive the growth of this segment. Moreover, the key advantage of the hospital pharmacy segment is that it also dispenses biological agents, parental drugs, and even chemotherapy medications, thus, accounting for the growth of this segment and thereby augmenting the overall development of the osteoporosis treatment market.
Osteoporosis Treatment Market by Region
The global osteoporosis treatment market has been segmented based on regions into North America, Europe, Asia Pacific, and the Rest of the World. North America holds the largest share of the global osteoporosis treatment market. The growth of this regional market can be majorly attributed to the enormous base for the aged population, thus, resulting in the development of osteoporosis cases among the people. According to the general studies by researchers and other organizations (such as WHO, American Society for Bone and Mineral Research (ASBMR), and International Osteoporosis Foundation), it is observed that women during postmenopausal majorly suffer from severe osteoporosis due to low bone mass and prior vertebral fracture. Additionally, growing research activities for enhanced drugs and treatment therapies also contribute to the growth of this regional market. For instance, in 2020, Celltrion Healthcare Co., Ltd. announced the initiation of the phase 1 study of its denosumab biosimilar, which is a monoclonal antibody injection that targets receptor activator of nuclear factor kappa-Β ligand (RANKL) proteins in patients with osteoporosis. Moreover, high awareness about early diagnosis with the available treatment for osteoporosis encourages the further development of this market. The presence of key players and continuously growing strategic collaboration and/or partnerships among them further drive the osteoporosis treatment market in North America, thus assisting in relieving this region's high osteoporosis burden.
Competitive Landscape
The prominent players operating in the global osteoporosis treatment market are:
The global osteoporosis treatment market in 2021 was US$ 12.5 billion.
The adverse effects of osteoporotic medications and stringent regulatory policies are significant global osteoporosis treatment market challenges.
The global osteoporosis treatment market is expected to grow at a CAGR of 3.6% in the forecast period.
Amgen Inc., F. Hoffmann La Roche Ltd., Allergan Plc, Novartis AG, Pfizer Inc., Merck and Co AG, Actavis Plc., GlaxoSmithKline Pharmaceutical Ltd., Teva Pharmaceuticals Industries Ltd., Novo Nordisk A/S, Sanofi S.A., Eli Lilly and Company, and Dr. Reddy's Laboratories are some of the major players in the market.
The bisphosphonate (BP) segment accounted for the largest share of the osteoporosis treatment market.
*Insights on financial performance are subject to the availability of information in the public domain
Using the fundamental research and knowledge services capabilities of GRG Health, Growth Plus Reports may now be tailored based on client needs.
GRG Health's unique GrowthMIX strategy and comprehensive research methodology enable us to provide unique and valuable insights to our clients while uncovering trends that would not be discovered using traditional techniques.
Snehal Deshmukh
Principle Consultant
Speak to analyst